Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone

Tseng Chin-Hsiao

Table 2 Incidence rates of dementia and hazard ratios by acarbose exposure in all patients and in different sexes.

Models n N Person-years Incidence rate (per 100,000 person-years) Adjusted hazard ratio 95% Confidence interval P-value All patients Acarbose never users 264 15524 64834.36 407.19 1.000 Acarbose ever users 231 15524 68355.38 337.94 0.841 (0.704-1.005) 0.0561 Cumulative duration of acarbose therapy treated as a continuous variable For every 1-year increment of acarbose use 0.918 (0.845-0.998) 0.0444 Men Acarbose never users 101 8358 34603.53 291.88 1.000 Acarbose ever users 107 8443 37111.21 288.32 0.934 (0.710-1.228) 0.6252 Cumulative duration of acarbose therapy treated as a continuous variable For every 1-year increment of acarbose use 0.983 (0.871-1.110) 0.7840 Women Acarbose never users 163 7166 30230.84 539.18 1.000 Acarbose ever users 124 7081 31244.17 396.87 0.783 (0.618-0.992) 0.0425 Cumulative duration of acarbose therapy treated as a continuous variable For every 1-year increment of acarbose use 0.870 (0.775-0.976) 0.0180